{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:25:14Z","timestamp":1772119514106,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2014,11,6]],"date-time":"2014-11-06T00:00:00Z","timestamp":1415232000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1007\/s10620-014-3422-x","type":"journal-article","created":{"date-parts":[[2014,11,5]],"date-time":"2014-11-05T05:48:55Z","timestamp":1415166535000},"page":"1031-1035","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["Hepatic Decompensation Likely Attributable to Simeprevir in Patients with Advanced Cirrhosis"],"prefix":"10.1007","volume":"60","author":[{"given":"Jonathan G.","family":"Stine","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Intagliata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neeral L.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Curtis K.","family":"Argo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen H.","family":"Caldwell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James H.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick G.","family":"Northup","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,11,6]]},"reference":[{"key":"3422_CR1","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1056\/NEJMoa1214853","volume":"368","author":"E Lawitz","year":"2013","unstructured":"Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368:1878\u20131887.","journal-title":"N Engl J Med"},{"key":"3422_CR2","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1002\/hep.26641","volume":"58","author":"MW Fried","year":"2013","unstructured":"Fried MW, Buti M, Dore GJ, et al. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naive genotype 1 hepatitis C: the randomized PILLAR study. Hepatology. 2013;58:1918\u20131929.","journal-title":"Hepatology"},{"key":"3422_CR3","doi-asserted-by":"crossref","first-page":"430.e436","DOI":"10.1053\/j.gastro.2013.10.058","volume":"146","author":"S Zeuzem","year":"2014","unstructured":"Zeuzem S, Berg T, Gane E, et al. Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial. Gastroenterology. 2014;146:430.e436\u2013441.e436.","journal-title":"Gastroenterology"},{"key":"3422_CR4","unstructured":"Gilead. In: Sofosbuvir Drug Package Insert. http:\/\/www.olysio.com\/shared\/product\/olysio\/prescribing-information.pdf . Accessed May 29, 2014."},{"key":"3422_CR5","unstructured":"FDA. Simeprevir Hearing. http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/AntiviralDrugsAdvisoryCommittee\/UCM375113.pdf ; 2013. Accessed June 20, 2014."},{"key":"3422_CR6","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.clinthera.2012.12.017","volume":"35","author":"M Sitole","year":"2013","unstructured":"Sitole M, Silva M, Spooner L, Comee MK, Malloy M. Telaprevir versus boceprevir in chronic hepatitis C: a meta-analysis of data from phase II and III trials. Clin Ther. 2013;35:190\u2013197. doi: 10.1016\/j.clinthera.2012.12.017 .","journal-title":"Clin Ther"},{"key":"3422_CR7","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.jhep.2013.11.013","volume":"60","author":"S Tischer","year":"2014","unstructured":"Tischer S, Fontana RJ. Drug-drug interactions with oral anti-HCV agents and idiosyncratic hepatotoxicity in the liver transplant setting. J Hepatol. 2014;60:872\u2013884. doi: 10.1016\/j.jhep.2013.11.013 .","journal-title":"J Hepatol"},{"key":"3422_CR8","unstructured":"Simeprevir prescribing information. http:\/\/www.olysio.com\/shared\/product\/olysio\/prescribing-information.pdf . Accessed June 14, 2014."},{"key":"3422_CR9","doi-asserted-by":"crossref","unstructured":"Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet. 2014. doi: 10.1016\/S0140-6736(14)61036-9 .","DOI":"10.1016\/S0140-6736(14)61036-9"},{"key":"3422_CR10","volume-title":"Recommendations for Testing, Managing, and Treating Hepatitis C","author":"AASLD Practice Guidlines","year":"2014","unstructured":"AASLD Practice Guidlines. Recommendations for Testing, Managing, and Treating Hepatitis C. New York: AASLD; 2014."},{"key":"3422_CR11","doi-asserted-by":"crossref","unstructured":"EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2014;60:392\u2013420. doi: 10.1016\/j.jhep.2013.11.003 .","DOI":"10.1016\/j.jhep.2013.11.003"},{"key":"3422_CR12","doi-asserted-by":"crossref","unstructured":"Stine JG, Lewis JH. Hepatotoxicity of antibiotics: a review and update for the clinician. Clin Liver Dis. 2013;17:609\u2013642, ix.","DOI":"10.1016\/j.cld.2013.07.008"},{"key":"3422_CR13","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1517\/17425255.2011.577415","volume":"7","author":"JG Stine","year":"2011","unstructured":"Stine JG, Lewis JH. Drug-induced liver injury: a summary of recent advances. Expert Opin Drug Metab Toxicol. 2011;7:875\u2013890.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"3422_CR14","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s40290-013-0015-5","volume":"27","author":"JH Lewis","year":"2013","unstructured":"Lewis JH. Drug-induced liver injury throughout the drug development life cycle: where we have been, where we are now, and where we are headed perspectives of a clinical hepatologist. Pharm Med. 2013;27:165\u2013191.","journal-title":"Pharm Med"},{"key":"3422_CR15","doi-asserted-by":"crossref","unstructured":"Poveda E, Wyles DL, Mena A, Pedreira JD, Castro-Iglesias A, Cachay E. Update on hepatitis C virus resistance to direct-acting antiviral agents. Antiviral Res. 2014;108:181\u2013191. doi: 10.1016\/j.antiviral.2014.05.015 .","DOI":"10.1016\/j.antiviral.2014.05.015"},{"key":"3422_CR16","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0140-6736(14)60538-9","volume":"384","author":"M Manns","year":"2014","unstructured":"Manns M, Marcellin P, Poordad F, et al. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2014;384:414\u2013426.","journal-title":"Lancet"},{"key":"3422_CR17","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.antiviral.2014.02.011","volume":"105","author":"MD Schneider","year":"2014","unstructured":"Schneider MD, Sarrazin C. Antiviral therapy of hepatitis C in 2014: do we need resistance testing? Antiviral Res. 2014;105:64\u201371.","journal-title":"Antiviral Res"},{"key":"3422_CR18","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0140-6736(14)60494-3","volume":"384","author":"IM Jacobson","year":"2014","unstructured":"Jacobson IM, Dore GJ, Foster GR, et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2014;384:403\u2013413.","journal-title":"Lancet"},{"key":"3422_CR19","doi-asserted-by":"crossref","first-page":"1669.e1663","DOI":"10.1053\/j.gastro.2014.02.051","volume":"146","author":"X Forns","year":"2014","unstructured":"Forns X, Lawitz E, Zeuzem S, et al. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial. Gastroenterology. 2014;146:1669.e1663\u20131679.e1663.","journal-title":"Gastroenterology"},{"key":"3422_CR20","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1128\/AAC.01452-09","volume":"54","author":"O Lenz","year":"2010","unstructured":"Lenz O, Verbinnen T, Lin TI, et al. In vitro resistance profile of the hepatitis C virus NS3\/4A protease inhibitor TMC435. Antimicrob Agents Chemother. 2010;54:1878\u20131887.","journal-title":"Antimicrob Agents Chemother"},{"key":"3422_CR21","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.2174\/092986706778773059","volume":"13","author":"S Russmann","year":"2006","unstructured":"Russmann S, Grattagliano I, Portincasa P, Palmieri VO, Palasciano G. Ribavirin-induced anemia: mechanisms, risk factors and related targets for future research. Curr Med Chem. 2006;13:3351\u20133357.","journal-title":"Curr Med Chem"},{"key":"3422_CR22","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1111\/apt.12324","volume":"37","author":"JH Lewis","year":"2013","unstructured":"Lewis JH, Stine JG. Review article: prescribing medications in patients with cirrhosis\u2014a practical guide. Aliment Pharmacol Ther. 2013;37:1132\u20131156.","journal-title":"Aliment Pharmacol Ther"},{"key":"3422_CR23","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1053\/j.gastro.2009.10.033","volume":"138","author":"HW Reesink","year":"2010","unstructured":"Reesink HW, Fanning GC, Farha KA, et al. Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients. Gastroenterology. 2010;138:913\u2013921.","journal-title":"Gastroenterology"},{"key":"3422_CR24","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","volume":"370","author":"N Afdhal","year":"2014","unstructured":"Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370:1889\u20131898. doi: 10.1056\/NEJMoa1402454 .","journal-title":"N Engl J Med"},{"key":"3422_CR25","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S0168-8278(03)00410-0","volume":"39","author":"H Kojima","year":"2003","unstructured":"Kojima H, Nies AT, Konig J, et al. Changes in the expression and localization of hepatocellular transporters and radixin in primary biliary cirrhosis. J Hepatol. 2003;39:693\u2013702.","journal-title":"J Hepatol"},{"key":"3422_CR26","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1053\/jhep.2001.29306","volume":"34","author":"N Chalasani","year":"2001","unstructured":"Chalasani N, Gorski JC, Patel NH, Hall SD, Galinsky RE. Hepatic and intestinal cytochrome P450 3A activity in cirrhosis: effects of transjugular intrahepatic portosystemic shunts. Hepatology. 2001;34:1103\u20131108.","journal-title":"Hepatology"},{"key":"3422_CR27","doi-asserted-by":"crossref","first-page":"3348","DOI":"10.1007\/s10620-013-2812-9","volume":"58","author":"M Juneja","year":"2013","unstructured":"Juneja M, Euliano R, Satoskar R, Lewis JH. Polypharmacy and comorbidity are associated with a lower early virologic response in hepatitis C patients treated with first generation protease inhibitor triple therapy: a preliminary analysis. Dig Dis Sci. 2013;58:3348\u20133358. doi: 10.1007\/s10620-013-2812-9 .","journal-title":"Dig Dis Sci"},{"key":"3422_CR28","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s12072-008-9106-x","volume":"3","author":"SK Sarin","year":"2009","unstructured":"Sarin SK, Kumar A, Almeida JA, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL). Hepatol Int. 2009;3:269\u2013282.","journal-title":"Hepatol Int"},{"key":"3422_CR29","doi-asserted-by":"crossref","unstructured":"Hezode C, Fontaine H, Dorival, C, et al. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. Gastroenterology. 2014;147(1):132.e4\u2013142.e4. doi: 10.1053\/j.gastro.2014.03.051 .","DOI":"10.1053\/j.gastro.2014.03.051"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-014-3422-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10620-014-3422-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-014-3422-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T15:44:20Z","timestamp":1559231060000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10620-014-3422-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,6]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["3422"],"URL":"https:\/\/doi.org\/10.1007\/s10620-014-3422-x","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725227429.793501444","asserted-by":"object"}]},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,6]]}}}